Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 May 9;31(3):321-323.
doi: 10.1080/08998280.2018.1463036. eCollection 2018 Jul.

Acute kidney injury and undiagnosed immunoglobulin A nephropathy after dabigatran therapy

Laurie Jansky  1 , Pallavi Mukkamala  1 , Deborah Jebakumar  2 , Arundhati Rao  2 , Tove M Goldson  1 , Samuel N Forjuoh  1
Affiliations
Case Reports

Acute kidney injury and undiagnosed immunoglobulin A nephropathy after dabigatran therapy

Laurie Jansky et al. Proc (Bayl Univ Med Cent). .

Abstract

Dabigatran, a new oral anticoagulant, is a direct thrombin inhibitor used as an alternative to warfarin to reduce the risk of stroke and systemic embolism with nonvalvular atrial fibrillation. We report a case of a man who resumed dabigatran after 6 weeks of prior therapy and began experiencing hematuria with worsening kidney function. Renal biopsy with immunofluorescence and electron microscopy showed mesangial deposits consistent with immunoglobulin A nephropathy. With discontinuation of dabigatran and addition of methylprednisolone, the gross hematuria cleared and urine output improved.

Keywords: Acute kidney injury; dabigatran; hematuria; immunoglobulin A nephropathy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Serum creatinine prior to and during the patient's hospitalization with a steady upward trend peaking on hospital day 11. (Day 1 corresponds to the day of hospital admission.)
See this image and copyright information in PMC

References

    1. Blommel MM, Blommel AL. Dabigatran etexilate: a novel oral direct thrombin inhibitor. Am J Health Syst Pharm. 2011;68:1506–1519. doi:10.2146/ajhp100348. - DOI - PubMed
    1. Boehringer Ingelheim US FDA approves Pradaxa (dabigatran etexilate—a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation [press release]. October 20, 2010. https://www.businesswire.com/news/home/20101020005862/en/FDA-Approves-Pr.... Accessed March28, 2018.
    1. Escoli R, Santos P, Andrade S, Carvalho F. Dabigatran-related nephropathy in a patient with undiagnosed IgA nephropathy. Case Rep Nephrol. 2015;2015:298261. doi:10.1155/2015/298261. - DOI - PMC - PubMed
    1. Ryan M, Ware K, Qamri Z, et al.. Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. Nephrol Dial Transplant. 2014;29:2228–2234. doi:10.1093/ndt/gft380. - DOI - PubMed
    1. Martin Cleary C, Moreno JA, Fernandez B, et al.. Glomerular haematuria, renal interstitial haemorrhage and acute kidney injury. Nephrol Dial Transplant. 2010;25:4103–4106. doi:10.1093/ndt/gfq493. - DOI - PubMed

Publication types

LinkOut - more resources